We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB

News   Jun 13, 2012

 
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
 
 
Advertisement
 

RELATED ARTICLES

Drug Shown To Modulate the Inflammatory Response in Severe COVID-19

News

Scientists have identified a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

READ MORE

Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer

News

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to trial results.

READ MORE

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE